Payment overview · 2025
General Payments
$363.85
4 reported records · 3 companies
Healthcare provider profile · identity verified
Vishal Sharma, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRADENTON, FL · NPI 1750464004
Verified facts
What the public records show
CMS Open Payments records show Vishal Sharma, MD received $363.85 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 68.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $248.26 | 68.2% | 2 | 2025 |
| DENTSPLY LLC | Unresolved — no canonical attribution shown | $98.00 | 26.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.59 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $265.85 | 3 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $98.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $127.40 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.86 | 1 | 2025 |
Source payment records
|
|||||
| Cerec Normalized: cerec |
Device | DENTSPLY LLC | $98.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
98 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 682 | 222 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 585 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 572 | 182 |
| Levothyroxine Sodium | Levothyroxine Sodium | 401 | 123 |
| Lisinopril | Lisinopril | 383 | 126 |
| Metformin Hcl | Metformin Hcl | 329 | 106 |
| Losartan Potassium | Losartan Potassium | 302 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 269 | 88 |
| Omeprazole | Omeprazole | 265 | 90 |
| Gabapentin | Gabapentin | 261 | 91 |
| Simvastatin | Simvastatin | 260 | 78 |
| Furosemide | Furosemide | 241 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 239 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 228 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 195 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 58 |
| Alprazolam | Alprazolam | 189 | 54 |
| Potassium Chloride | Potassium Chloride | 171 | 62 |
| Glimepiride | Glimepiride | 159 | 54 |
| Allopurinol | Allopurinol | 153 | 54 |
| Methylprednisolone | Methylprednisolone | 146 | 125 |
| Eliquis | Apixaban | 138 | 38 |
| Ezetimibe | Ezetimibe | 135 | 49 |
| Ozempic | Semaglutide | 129 | 36 |
| Sertraline Hcl | Sertraline Hcl | 120 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 120 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 41 |
| Alendronate Sodium | Alendronate Sodium | 110 | 35 |
| Trazodone Hcl | Trazodone Hcl | 109 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 34 |
| Meloxicam | Meloxicam | 99 | 38 |
| Mounjaro | Tirzepatide | 99 | 18 |
| Farxiga | Dapagliflozin Propanediol | 98 | 24 |
| Montelukast Sodium | Montelukast Sodium | 96 | 31 |
| Mirtazapine | Mirtazapine | 93 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 23 |
| Atenolol | Atenolol | 80 | 24 |
| Azithromycin | Azithromycin | 78 | 68 |
| Trulicity | Dulaglutide | 77 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 23 |
| Donepezil Hcl | Donepezil Hcl | 71 | 25 |
| Clonazepam | Clonazepam | 69 | 24 |
| Prednisone | Prednisone | 69 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 52 |
| Tramadol Hcl | Tramadol Hcl | 64 | 25 |
| Xarelto | Rivaroxaban | 63 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 21 |
| Nifedipine Er | Nifedipine | 59 | 16 |
| Temazepam | Temazepam | 59 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 15 |
| Glipizide | Glipizide | 57 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | 13 |
| Carvedilol | Carvedilol | 51 | 20 |
| Spironolactone | Spironolactone | 51 | 19 |
| Famotidine | Famotidine | 50 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Valsartan | Valsartan | 49 | 18 |
| Celecoxib | Celecoxib | 48 | 13 |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Jardiance | Empagliflozin | 47 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 24 |
| Clonidine Hcl | Clonidine Hcl | 41 | 14 |
| Finasteride | Finasteride | 41 | 15 |
| Fenofibrate | Fenofibrate | 40 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 11 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Prolia | Denosumab | 37 | 26 |
| Tradjenta | Linagliptin | 37 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | 11 |
| Terazosin Hcl | Terazosin Hcl | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | 11 |
| Creon | Lipase/Protease/Amylase | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 22 |
| Metformin Hcl Er | Metformin Hcl | 34 | 11 |
| Synthroid | Levothyroxine Sodium | 34 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 34 | 14 |
| Lorazepam | Lorazepam | 33 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 32 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 11 |
| Bupropion Xl | Bupropion Hcl | 30 | 13 |
| Cefdinir | Cefdinir | 30 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 13 |
| Midodrine Hcl | Midodrine Hcl | 29 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Klor-Con 10 | Potassium Chloride | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 24 |
| Colchicine | Colchicine | 25 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 24 |
| Primidone | Primidone | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 15 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Modafinil | Modafinil | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 20 |
| Mupirocin | Mupirocin | 20 | 15 |
| Testosterone | Testosterone | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Ibu | Ibuprofen | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $363.85 · 4 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, Cerec, GARDASIL 9 | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error